View Older Stories View More Recent Stories

Sep 2, 2021 08:30AM Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
Aug 12, 2021 04:01PM Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 5, 2021 09:00AM Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
Aug 4, 2021 08:08AM Capricor Therapeutics (CAPR) Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
Aug 4, 2021 08:00AM Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock
Jul 27, 2021 08:08AM Capricor Therapeutics (CAPR) Appoints Karimah Es Sabar to its Board
Jul 27, 2021 08:00AM Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
Jun 17, 2021 09:00AM Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
Jun 10, 2021 09:15AM Capricor Therapeutics to Participate in BIO Digital 2021 Conference
May 18, 2021 08:30AM Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting
May 13, 2021 04:05PM Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021 09:00AM Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
May 6, 2021 08:30AM Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
Apr 29, 2021 08:00AM Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
Mar 11, 2021 04:01PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Mar 9, 2021 09:15AM Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
Mar 4, 2021 09:00AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
Feb 1, 2021 09:15AM Capricor Therapeutics (CAPR) Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
Feb 1, 2021 09:15AM Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
Jan 19, 2021 09:15AM Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
Jan 12, 2021 09:05AM Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Dec 29, 2020 09:15AM Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
Nov 24, 2020 07:35AM Capricor Therapeutics (CAPR) Begins Patient Dosing in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
Nov 24, 2020 07:30AM Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
Nov 12, 2020 04:01PM Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 9, 2020 09:15AM Capricor Therapeutics (CAPR) Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
Nov 9, 2020 09:15AM Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
Nov 5, 2020 09:00AM Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12
Sep 23, 2020 09:25AM Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
Sep 10, 2020 09:15AM Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Aug 31, 2020 09:00AM Capricor Therapeutics to Present at The LD 500 Virtual Conference
Aug 25, 2020 09:19AM Capricor Therapeutics (CAPR) Reports FDA Acceptance of IND Application for Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
Aug 25, 2020 09:15AM Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
Aug 6, 2020 04:01PM Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 30, 2020 09:15AM Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
Jun 4, 2020 09:15AM Capricor to Participate in BIO Digital International Convention
May 26, 2020 09:25AM Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
May 14, 2020 04:01PM Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020 04:30PM Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
May 13, 2020 07:04AM Capricor Therapeutics (CAPR) HOPE-2 Study in Patients with DMD Treated with Lead Candidate CAP-1002 Showed Improvements in Upper Limb, Cardiac and Respiratory function
May 13, 2020 07:00AM Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
Apr 29, 2020 09:17AM Capricor Therapeutics (CAPR) announces 100 percent survival in critical COVID-19 patients in CAP-1002 Study
Apr 29, 2020 09:15AM New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002
Apr 13, 2020 09:00AM Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
Apr 3, 2020 08:00AM Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy
Mar 24, 2020 08:00AM Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development
Mar 18, 2020 04:01PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Nov 7, 2019 04:00PM Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
Nov 1, 2019 09:00AM Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
Oct 21, 2019 09:25AM Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
View More Recent Stories View Older Stories